Kaposi's sarcoma of the head and neck in patients with acquired immunodeficiency syndrome

1994 ◽  
Vol 111 (5) ◽  
pp. 618-624 ◽  
Author(s):  
B SINGH ◽  
G HAREL ◽  
F LUCENTE
1994 ◽  
Vol 111 (5) ◽  
pp. 618-624 ◽  
Author(s):  
Bhuvanesh Singh ◽  
Gady Har-El ◽  
Frank E. Lucente

Kaposi's sarcoma is the most common neoplastic process in patients infected with the human immunodeficiency virus. Moreover, the occurrence of Kaposi's sarcoma in human immunodeficiency virus—infected patients advances their classification to having the acquired immunodeficiency syndrome. We reviewed the medical records of 48 patients with human immunodeficiency virus infection who had Kaposi's sarcoma documented on their initial visit to the hospital. The onset of Kaposi's sarcoma occurred independent of the Centers for Disease Control and Prevention classification of human immunodeficiency virus infection (modified to exclude Kaposi's sarcoma). This neoplasm developed more frequently in patients who acquired human immunodeficiency virus infection by sexual contact (75% of cases), but manifestations were not significantly different in any of the risk populations for human immunodeficiency virus infection. Kaposi's sarcoma lesions were unpredictable and either showed progression, remained static, or occasionally, regressed spontaneously. Moreover, the lesions were usually multifocal at presentation, with the head and neck (62.5% of cases) as the primary site of involvement. In this region cutaneous lesions predominated (66.7%), followed by mucosal (56.7%) and deep structure (13.3%) involvement. The majority of patients with acquired immunodeficiency syndrome Kaposi's sarcoma involving head and neck structures were asymptomatic (80% of cases). Mucosal lesions were associated with symptoms in 29.3% of cases, whereas cutaneous lesions had symptoms in 5% of cases.


Ophthalmology ◽  
1983 ◽  
Vol 90 (8) ◽  
pp. 879-884 ◽  
Author(s):  
Abe M. Macher ◽  
Alan Palestine ◽  
Henry Masur ◽  
Gail Bryant ◽  
Chi-Chao Chan ◽  
...  

1986 ◽  
Vol 4 (4) ◽  
pp. 544-551 ◽  
Author(s):  
F X Real ◽  
H F Oettgen ◽  
S E Krown

The efficacy of recombinant leukocyte A interferon (rIFN-alpha A [Roferon-A, Hoffman-La Roche, Nutley, NJ]) treatment of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome was evaluated in sequential trials using high doses (36 X 10(6) units) and low doses (3 X 10(6) units) of interferon. A major response was seen in 38% of patients treated at the high dose, with a median response duration of 18 months. At the low dose, the major response rate was 3%; dose escalation to 36 X 10(6) units resulted in an additional major response rate of 17% in low-dose nonresponders, with a median response duration of 10 months. Four of 11 patients who achieved a complete response remain free of disease, whereas all partial responders have shown disease progression. Unacceptable toxicity occurred in 27% of patients initially treated at the high dose and only in 10% of those who had progressive dose escalation up to 36 X 10(6) units. Prior opportunistic infections correlated negatively with therapeutic response, whereas large tumor burden and gastrointestinal involvement did not. Responding patients showed a significantly longer survival and a lower incidence of subsequent opportunistic infections than nonresponders. However, from our study we cannot determine whether rIFN-alpha A has an effect on the natural history of Kaposi's sarcoma in patients with the acquired immunodeficiency syndrome.


1992 ◽  
Vol 59 (6) ◽  
pp. 80-83
Author(s):  
M. Guy ◽  
D. Singer ◽  
Y. Arieli ◽  
S. Eisenkfraft

We report two cases of primary Kaposi's sarcoma limited to the glans penis. In circumcised men the basic lesion appears as a reddish-violet nodule. The patients denied homosexuality, drug abuse or blood transfusion. Excision of the lesion with wide margins and radiotherapy was adequate therapy. Serological investigations for HIV were all negative. At two years and one year after operation the patients are well with normal serology.


Sign in / Sign up

Export Citation Format

Share Document